Skip to main content

Table 6 Antiviral efficacy in patients with COVID-19

From: Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19

  Severe (n = 178) Non-severe (n = 372)
Ribavirin 7/17 41.2% 22/23 95.7%
Oseltamivir 34/53 64.2% 49/49 100.0%
Arbidol 22/30 73.3% 109/110 99.1%
Lopinavir/ritonavir 0/0 2/2 100%
Ribavirin+Oseltamivir 9/20 45.0% 38/38 100%
Ribavirin+Arbidol 12/12 100% 18/19 94.7%
Arbidol+Oseltamivir 15/17 88.2% 14/16 87.5%
  1. The data were expressed in the form of n/N (%), where n represents the number of patients with clinical disease improvement, N represents the total number of patients receiving corresponding drugs